NCT06766552View on ClinicalTrials.gov

A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.

Not yet recruitingOBSERVATIONAL
Enrollment

10,000

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

December 30, 2029

Study Completion Date

June 30, 2030

Conditions
Ankylosing Spondylitis (AS)Psoriatic Arthritis (PsA)Nr-axSpAPolymyalgia Rheumatica (PMR)Takayasu Arteritis (TAK)Giant Cell Arteritis (GCA)Behcet's DiseaseEnthesitis-related Arthritis
Trial Locations (1)

Unknown

The Second Affiliated Hospital of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT06766552 - A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases. | Biotech Hunter | Biotech Hunter